PMID- 15448029
OWN - NLM
STAT- MEDLINE
DCOM- 20041201
LR  - 20201212
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 10
IP  - 18 Pt 2
DP  - 2004 Sep 15
TI  - Dendritic cell-tumor fusion vaccines for renal cell carcinoma.
PG  - 6347S-52S
AB  - Renal cell carcinoma is a malignant disease that demonstrates resistance to 
      standard chemotherapeutic agents. A promising area of investigation is the use of 
      cancer vaccines to educate host immunity to specifically target and eliminate 
      malignant cells. Dendritic cells (DCs) are potent antigen-presenting cells that 
      are uniquely effective in generating primary immune responses. DCs that are 
      manipulated to present tumor antigens induce antitumor immunity in animal models 
      and preclinical human studies. A myriad of strategies have been developed to 
      effectively load tumor antigen onto DCs, including the introduction of individual 
      peptides, proteins, or tumor-specific genes, as well as the use of whole tumor 
      cells as a source of antigen. A promising approach for the design of cancer 
      vaccines involves the fusion of whole tumor cells with DCs. The DC-tumor fusion 
      presents a spectrum of tumor-associated antigens to helper and cytotoxic T-cell 
      populations in the context of DC-mediated costimulatory signals. In animal 
      models, vaccination with DC-tumor fusions resulted in protection from tumor 
      challenge and regression of established metastatic disease. We have conducted 
      phase 1 dose escalation studies in which patients with metastatic breast and 
      renal cancer underwent vaccination with DC-tumor fusions. Twenty-three patients 
      underwent vaccination with autologous DC-tumor fusions. Vaccination was well 
      tolerated without substantial treatment-related toxic effects. Immunologic 
      responses and disease regression were observed in a subset of patients. Future 
      studies will explore the effect of DC maturation and cytokine adjuvants on 
      vaccine potency.
FAU - Avigan, David
AU  - Avigan D
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. 
      davigan@caregroup.harvard.edu
LA  - eng
GR  - N01-C0-12400/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/*immunology
MH  - *Cancer Vaccines
MH  - Carcinoma, Renal Cell/*immunology
MH  - Dendritic Cells/*immunology
MH  - Disease Models, Animal
MH  - Humans
MH  - Kidney Neoplasms/*immunology
MH  - Recombinant Fusion Proteins/immunology
RF  - 62
EDAT- 2004/09/28 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/09/28 05:00
PHST- 2004/09/28 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/09/28 05:00 [entrez]
AID - 10/18/6347S [pii]
AID - 10.1158/1078-0432.CCR-050005 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6347S-52S. doi: 
      10.1158/1078-0432.CCR-050005.